Lilly Obesity Drugs Lag Wegovy in Early Prescription Data, Weighing on Stock
TL;DR Summary
Premarket, Eli Lilly shares fell after IQVIA data cited by Bloomberg showed Lilly’s obesity drugs Foundayo (oral) and Zepbound trailed Novo Nordisk’s Wegovy in weekly prescriptions; Zepbound fell about 2% week over week while Wegovy rose about 7% in the same period, and Foundayo posted 3,707 prescriptions in its first full week versus Wegovy’s roughly 18,410 in its first full week; analysts caution that one week of data isn’t definitive, but weak early momentum could pressure Lilly stock if the trend persists.
- Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy Seeking Alpha
- Lilly's obesity pill records modest second week as battle with Novo intensifies Reuters
- Battle Of The Weight-Loss Pills Continues With A Shocking Twist Investor's Business Daily
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics BioPharma Dive
- Lilly’s New Obesity Pill Off to Slow Start in Race With Novo Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
3 min
vs 4 min read
Condensed
87%
613 → 82 words
Want the full story? Read the original article
Read on Seeking Alpha